Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.

Clinical pharmacology and therapeutics - 1 Jun 2006

Hermann Monica, Bogsrud Martin P, Molden Espen, Asberg Anders, Mohebi Beata U, Ose Leiv, Retterstøl Kjetil

Abstract excerpt

BACKGROUND: The most serious side effect from statin treatment is myopathy, which may proceed to rhabdomyolysis. This is the first study to investigate whether the pharmacokinetics of either atorvastatin or its metabolites, or both, is altered in patients with atorvastatin-related myopathy compared with healthy controls. METHODS: A 24-hour pharmacokinetic investigation was performed in 14 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Creatine Kinase

Share to Creatinine

Share to Heptanoic Acids

Share to Lactones

Share to Liver-Specific Organic Anion Transporter 1

Share to Pyrroles

Source

Identifiers

PMID: 16765141
DOI: 10.1016/j.clpt.2006.02.014

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.PMID 16765141Read ↗

Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.Semantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle ComponentsSemantic proximity Read ↗

Statin-associated myopathy: from genetic predisposition to clinical management.Semantic proximity Read ↗

Approach to clinical and genetic characterization of statin-induced myopathy.Semantic proximity Read ↗

Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.Semantic proximity Read ↗

Genetic Polymorphisms in Drug Transporter Genes (ABCB1, OATP1B1) and Their Impact on Statin Pharmacokinetics and Myopathy RiskSemantic proximity Read ↗

Statin-associated muscle toxicity : clinical and genomic perspectivesSemantic proximity Read ↗

UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.Semantic proximity Read ↗

Clinical implications of pharmacogenetic variation on the effects of statins.Semantic proximity Read ↗

Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic VariantsSemantic proximity Read ↗

Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.